REPL: Replimune Group Inc

REPL新闻

• 15:03 Replimune stock collapses 64% following FDA rejection
• 03:04 Undercovered Stocks: Zscaler, Aeluma, Devon Energy, And More
• 20:30 U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.63%
• 20:30 美国股市上涨；截至收盘道琼斯工业平均指数上涨0.63%
• 17:44 FDA Rejection Sparks Questions On Replimune Drug Approval Path - Replimune Group (NASDAQ:REPL)
• 15:31 Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes
• 19:30 Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives (REPL)
• 15:19 FDA Review Looms As Replimune Faces Weak Technical Setup - Replimune Group (NASDAQ:REPL)
• 02:05 Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback (NASDAQ:IOVA)
• 16:16 RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease
• 15:53 CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer
• 16:15 Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
• 16:44 ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy
• 00:54 Tracking Baker Brothers Portfolio – Q4 2025 Update (NASDAQ:INCY)
• 15:38 COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM
• 15:33 Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug
• 15:31 JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
• 15:26 XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
• 13:27 Mirum Completes Enrollment & Screening in Liver Disease Studies
• 17:43 Bayer Advances Roundup Settlement With Missouri Court Approval
• 15:36 ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M
• 14:55 Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect?
• 10:30 MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines
• 04:46 Replimune Stock: Multiple Shots On Goal But A High Risk Binary Approaches (NASDAQ:REPL)